Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia

Neuroscience

Volumn 126, Issue 3, 2004, Pages 591-598

  Keilhoff, G ^a   Becker, A ^a   Grecksch, G ^a   Wolf, G ^a   Bernstein, H G ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

3,3 diaminobenzidine; animal model; DAB; GABA; gamma amino butyric acid; hippocampus; immunocytochemistry; NADPH; NADPHd; NMDA; reduced nicotinamide adenine dinucleotide phosphate; reduced nicotinamide adenine dinucleotide phosphate diaphorase

Indexed keywords

KETAMINE; NEURONAL NITRIC OXIDE SYNTHASE; PARVALBUMIN; PROTEIN C FOS; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SCHIZOPHRENIA; TISSUE DISTRIBUTION;

ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; GENES, FOS; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; KETAMINE; MALE; NADPH DEHYDROGENASE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; PARVALBUMINS; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

EID: 2942555278     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2004.03.039     Document Type: Article

References (48)

1. Akbarian S., Bunney W.E. Jr, Potkin S.G., Wigal S.B., Hagman J.O., Sand C.A., Jones E.G. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry. 50:1993;169-177
2. (2+) deficiency induce a long-term sensitization of the central nociceptive pathways? Eur J Pharmacol. 469:2003;65-69
3. Ananth C., Dheen S.T., Gopalakrishnakone P., Kaur C. Distribution of NADPH-diaphorase and expression of nNOS, N-methyl-D-aspartate receptor (NMDAR1) and non-NMDA glutamate receptor (GlutR2) genes in the neurons of the hippocampus after domoic acid-induced lesions in adult rats. Hippocampus. 13:2003;260-272
4. Beasley C.L., Zhang Z.J., Patten I., Reynolds G.P. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium binding proteins. Biol Psychiatry. 52:2002;708-715
5. Becker A., Peters B., Schroeder H., Mann T., Huether G., Grecksch G. Ketamine-induced changes in rat behaviour a possible animal model of schizophrenia. Prog. Neuropsychopharmacol Biol Psychiatry. 27:2003;687-700
6. Benes F.M., McSparren J., Bird E.D., SanGiovanni J.P., Vincent S.L. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry. 48:1991;996-1001
7. Benes F.M., Beretta S. GABAergic interneurons implications for understanding schizophrenia and bipolar disorders. Neuropsychopharmacology. 25:2001;21-27
8. Bernstein H.-G., Becker A., Keilhoff G., Spilker C., Gorczyca A., Braunewell K.-H., Grecksch G. Brain region-specific changes in the expression of calcium sensor proteins after repeated application of ketamine to rats. Neurosci Lett. 339:2003;95-98
9. Bernstein H.-G., Krell D., Braunewell K.-H., Baumann B., Gundelfinger E., Diekmann S., Danos P., Bogerts B. Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia. J Neurocytol. 30:2001;661-670
10. Bernstein H.-G., Stanarius A., Baumann B., Henning H., Krell D., Danos P., Falkai P., Bogerts B. Nitric oxide synthase-containing neurons in the human hypothalamus reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience. 83:1998;867-875
11. Bird D., Bujas-Bobanovic M., Robertson H.A., Dursan S.M. Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase. Psychopharmacology. 155:2001;299-309
12. Caillard O., Moreno H., Schwaller B., Llano I., Celio M.R., Marty A. Role of the calcium-binding protein parvalbumin in short-term synaptic plasticity. Proc Natl Acad Sci USA. 97:2000;13372-13377
13. Coyle J.T., Tsai G., Goff D.C. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Target CNS Neurol Disord. 1:2002;183-189
14. Danos P., Bauman B., Bernstein H.-G., Franz M., Stauch R., Northoff G., Krell D., Falkai P., Bogerts B. Schizophrenia and anteroventral thalamic nucleus selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons. Psychiatry Res. 82:1998;1-10
15. De Vry J., Jentzsch K.R. Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine. Behav Pharmacol. 14:2003;229-235
16. Duncan E.J., Madonick S.H., Parwani A., Angrist B., Rajan R., Chakravorty S., Efferen T.R., Szilagyi S., Stephanides M., Chappell B., Gonzenbach S., Ko G.N., Rotrosen J.P. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology. 25:2001;72-83
17. Duncan G.E., Miyamoto S., Leipzig J.N., Lieberman J.A. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res. 843:1999;171-183
18. Duncan G.E., Moy J.J., Knapp D.J., Mueller R.A., Breese G.R. Metabolic mapping of the rat brain after subanesthetic doses of ketamine potential relevance to schizophrenia. Brain Res. 787:1998;181-190
19. Gibson C.L., Clowry G.J. N-methyl-D-aspartate receptor blockade during development induces short-term but not long-term changes in c-Jun and parvalbumin expression in the rat cervical spinal cord. Exp Neurol. 170:2001;380-384
20. Heckers S., Konradi C. Hippocampal neurons in schizophrenia. J Neural Transm. 109:2002;891-905
21. Heckers S., Stone D., Walsh J., Shick J., Koul P., Benes F.M. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder schizophrenia. Arch Gen Psychiatry. 59:2002;521-529
22. Herdegen T., Kovary K., Buhl A., Bravo R., Zimmermann M., Gass P. Basal expression of the inducible transcription factors c-Jun, JunB, JunD, c-Fos, FosB, and Krox-24 in the adult rat brain. J Comp Neuol. 354:1995;39-56
23. Herken H., Uz E., Ozyurt H., Akyol O. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr Res. 52:2001;289-290
24. Hijazi Y., Bodonian C., Bolon M., Salord F., Boulieu R. Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury. Br J Anaesth. 90:2003;155-160
25. Kapur S., Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry. 7:2002;837-844
26. Kegeles L.S., Abi-Dargham A., Zea-Ponce Y., Rodenhiser-Hill J., Mann J.J., Van Heertum R.L., Cooper T.B., Carlsson A., Laruelle M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans implications for schizophrenia. Biol Psychiatry. 48:2000;627-640
27. Kontkanen O., Lakso M., Wong G., Castren E. Chronic antipsychotic drug treatment induces long-lasting expression of fos and jun family genes and activator protein 1 complex in the rat prefrontal cortex. Neuropsychopharmacology. 27:2002;152-162
28. Lindefors N., Barati S., O'Connor W.T. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Res. 759:1997;205-212
29. Masuzawa M., Nakao S., Miyamoto E., Yamada M., Murao K., Nishi K., Shingu K. Pentobarbital inhibits ketamine-induced dopamine release in the rat nucleus accumbens a microdialysis study. Anesth Analg. 96:2003;148-152
30. Mechri A., Saound M., Khiari G., d'Amato T., Dalery J., Gaha L. Glutaminergic hypothesis of schizophrenia clinical research studies with ketamine. Encephale. 27:2001;53-59
31. Mitchell I.J., Cooper A.J., Griffiths M.R., Barber D.J. Phencyclidine and corticosteroids induce apoptosis of a subpopulation of striatal neurons a neural substrate for psychosis? Neuroscience. 84:1998;489-501
32. Miyamoto S., Mailman R.B., Lieberman J.A., Duncan G.E. Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors. Brain Res. 894:2001;167-180
33. Moghaddam B., Adams A., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 17:1997;2921-2927
34. Necchi D., Virgili M., Monti B., Contestabile A., Scherini E. Regional alterations of the NO/NOS system in the aging brain a biochemical, histochemical and immunochemical study in the rat. Brain Res. 933:2002;31-41
35. Reynolds G.P., Beasley C.L. GABAergic neuronal subtypes in the human frontal cortex-development and deficits in schizophrenia. J Chem Neuroanat. 22:2001;95-100
36. Reynolds G.P., Zhang Z.J., Beasley C.L. Neurochemical correlates of cortical GABAergic deficits in schizophrenia selective losses of calcium binding protein immunoreactivity. Brain Res Bull. 55:2001;579-584
37. Reynolds G.P., Beasley C.L., Zhang Z.J. Understanding the neurotransmitter pathology of schizophrenia selective deficits of subtypes of cortical GABEergic neurons. J Neural Transm. 109:2002;881-889
38. Rothe F., Canzler U., Wolf G. Subcellular localization of the neuronal isoform of nitric oxide synthase in the rat brain a critical evaluation. Neuroscience. 83:1998;259-269
39. Savas H.A., Herken H., Yürekli M., Zu E., Tutkum H., Zoroglu S.S., Özan M.E., Cengiz B., Akyol Ö. Possible role of nitric oxide and adrenomedullin in bipolar affective disorders. Neuropsychobiology. 45:2002;57-61
40. Sayed M.A.N., Noda Y., Hamdy M.M., Mamiya T., Nagai T., Furukawa H., Nabeshima T. Enhancement of immobility induced by repeated phencyclidine injection association with c-Fos protein in the mouse brain. Behav Brain Res. 124:2001;71-76
41. Schroeder U., Schroeder H., Darius J., Grecksch G., Sabel B.A. Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants. Behav Brain Res. 97:1998;59-68
42. Ste-Marie L., Hazell A.S., Bemeur C., Butterworth R., Montgomery J. Immunohistochemical detection of inducible nitric oxide synthase, nitrotyrosine and manganese superoxide dismutase following hyperglycemic focal cerebral ischemia. Brain Res. 918:2001;10-19
43. Turner M.S., Mignon L., Napier T.C. Alterations in responses of ventral pallidal neurons to excitatory amino acids after long-term dopamine depletion. J Pharmacol Exp Ther. 301:2002;371-381
44. van Luijtelaar G., Fabene P.F., de Bruin N., Jongema C., Ellenbroek B.A., Veening J.G. Neural correlates of sensory gating in the rat decreased Fos induction in the lateral septum. Brain Res Bull. 54:2001;145-151
45. Veenman C.L., Lehmann J., Stöhr T., Totterdell S., Yee B., Mura A., Feldon J. Comparison of densities of NADPHd reactive and nNOS immunopositive neurons in the hippocampus of three age groups of young nonhandled and handled rats. Dev Brain Res. 114:1999;229-243
46. Xing G., Chavko M., Zhang L.X., Yang S., Post R.M. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr Res. 1:2002;21-30
47. Yanik M., Vural H., Kocyigit A., Tutkun H., Zoroglu S.S., Herken H., Savas H.A., Koylu A., Akyol O. Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia? Neuropsychobiology. 47:2003;61-65
48. Zhang Z., Reynolds G.P. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus of schizophrenia. Schizophr Res. 55:2002;1-10